logo
Post-Transformer Model Systems Can Drive Change

Post-Transformer Model Systems Can Drive Change

Forbes2 days ago
Chipset on circuit board for semiconductor industry, 3d rendering
What if you could have conventional large language model output with 10 times to 20 times less energy consumption?
And what if you could put a powerful LLM right on your phone?
It turns out there are new design concepts powering a new generation of AI platforms that will conserve energy and unlock all sorts of new and improved functionality, along with, importantly, capabilities for edge computing.
What is Edge Computing?
Edge computing occurs when the data processing and other workloads take place close to the point of origin, in other words, an endpoint, like a piece of data collection hardware, or a user's personal device.
Another way to describe it is that edge computing starts to reverse us back away from the cloud era, where people realized that you could house data centrally. Yes, you can have these kinds of vendor services, to relieve clients of the need to handle on-premises systems, but then you have the costs of transfer, and, typically, less control. If you can simply run operations locally on a hardware device, that creates all kinds of efficiencies, including some related to energy consumption and fighting climate change.
Enter the rise of new Liquid Foundation Models, which innovate from a traditional transformer-based LLM design, to something else.
A September 2024 piece in VentureBeat by Carl Franzen covers some of the design that's relevant here. I'll include the usual disclaimer: I have been listed as a consultant with Liquid AI, and I know a lot of the people at the MIT CSAIL lab where this is being worked on. But don't take my word for it; check out what Franzen has to say.
'The new LFM models already boast superior performance to other transformer-based ones of comparable size such as Meta's Llama 3.1-8B and Microsoft's Phi-3.5 3.8B,' he writes. 'The models are engineered to be competitive not only on raw performance benchmarks but also in terms of operational efficiency, making them ideal for a variety of use cases, from enterprise-level applications specifically in the fields of financial services, biotechnology, and consumer electronics, to deployment on edge devices.'
More from a Project Leader
Then there's this interview at IIA this April with Will Knight and Ramin Hasani, of Liquid AI.
Hasani talks about how the Liquid AI teams developed models using the brain of a worm: C elegans, to be exact.
He talked about the use of these post-transformer models on devices, cars, drones, and planes, and applications to predictive finance and predictive healthcare.
LFMs, he said, can do the job of a GPT, running locally on devices.
'They can hear, and they can talk,' he said.
More New Things
Since a recent project launch, Hasani said, Liquid AI has been having commercial discussions with big companies about how to apply this technology well to enterprise.
'People care about privacy, people care about secure applications of AI, and people care about low latency applications of AI,' he said. 'These are the three places where enterprise does not get the value from the other kinds of AI companies that are out there.'
Talking about how an innovator should be a 'scientist at heart,' Hasani went over some of the basic value propositions of having an LLM running offline.
Look, No Infrastructure
One of the main points that came out of this particular conversation around LFMs is that if they're running off-line on a device, you don't need the extended infrastructure of connected systems. You don't need a data center or cloud services, or any of that.
In essence, these systems can be low-cost, high-performance, and that's just one aspect of how people talk about applying a 'Moore's law' concept to AI. It means systems are getting cheaper, more versatile, and easier to manage – quickly.
So keep an eye out for this kind of development as we see smarter AI emerging.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Yahoo

time20 minutes ago

  • Yahoo

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Yahoo

time20 minutes ago

  • Yahoo

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Yahoo

time24 minutes ago

  • Yahoo

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store